Alto Neuroscience’s Astonishing Financial Results and Breakthrough Highlights
Alto Neuroscience has initiated a Phase 2 study of ALTO-203, a PDE4 inhibitor targeted at patients with major depressive...
Medidata: Enhancing Trials, Transforming Patient Care Worldwide
Medidata, a leading clinical trial solutions provider, has partnered with Worldwide Clinical Trials (Worldwide) to leverage Medidata AI. This...
Unlock the Incredible: OKLO & Atomic Alchemy Collaborate on Isotope Advancements
Oklo Inc., a provider of clean nuclear power and fuel recycling, has partnered with Atomic Alchemy Inc. to meet...
BridGene Biosciences and How It Aims to Target Hard to Drug Proteins
In this interview, Dr. Ping Cao, co-founder and CEO of BridGene Biosciences, discusses targeting “hard to drug” proteins that...
Empatica Platform Empowers Developers to Enhance Health Data Analysis
Empatica, a digital biomarker development and patient monitoring company, has integrated McRoberts’ 71 endpoints into its FDA-cleared Health Monitoring...
Baxter Secures Critical FDA Approval for Clinolipid’s Expanded Use
Baxter International has received FDA approval to expand the use of Clinolipid, a lipid emulsion, to include pediatric patients,...
Can-Fite BioPharma Proceeds with Phase 3 Liver Cancer Trial
Can-Fite BioPharma has secured approval from the FDA and EMA for a pivotal Phase 3 clinical trial for the...
Merck Terminates Investigational Melanoma Treatment Arm
Merck has terminated a clinical trial arm combining vibostolimab and pembrolizumab for treating resected high-risk melanoma. The decision was...
AC Immune and Takeda: A Remarkable Agreement for Alzheimer’s Therapy
Takeda Pharmaceutical Company and AC Immune have entered into an exclusive global option and licensing agreement for AC Immune’s...
Flatiron Health, Cancer Centers Align on Data Capture
Flatiron Health, a healthcare technology company, has joined forces with the Association of Cancer Care Centers (ACCC) to improve...